A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Key facts

Study ID
NCT03843125
Run by
Eli Lilly and Company
People needed
1147
Starts
2019-09-09
Expected to finish
2022-04-01
Last updated by the study team
2023-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.